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Comment
A decade ago, the question “why treat insomnia?”1 was 
posed to challenge the persistent perspective that only 
“primary” insomnia (ie, chronic insomnia not attributable 
to other disorders) warrants target treatment. That is, insom-
nia should be viewed as a symptom (like fever or headache) 
and that targeted treatment is only indicated when tempo-
rary relief is needed or until more comprehensive gains 
could be achieved with therapy for the parent or precipitat-
ing medical or psychiatric disorder.2,3 Implicit in this per-
spective and belief were 2 major corollaries that guided 
all considerations about treating insomnia: (1) that most 
insomnia is “secondary” (occurs in association with, and 
may be attributed to, other disorders)4 and (2) that second-
ary insomnia is only minimally responsive to targeted treat-
ment (because it occurs owing to disease specific factors). 
All 3 of these “axioms” are no longer foundational princi-
ples for many, if not most, within Sleep Medicine. What 
remains is for the arguments and evidence to be widely dis-
seminated throughout clinical health care. This brief mis-
sive is intended to bridge this gap.
In 2010, it was argued that chronic insomnia (3 or more 
days per week for 3 or more months), regardless of whether 
it was viewed as primary or secondary, should be treated 
given data regarding its prevalence, course, consequences, 
and costs.1 Chronic insomnia: occurs in approximately 10% 
of the population5 and in about 50% of patients in primary 
care;6 persists for decades;7,8 is a risk factor for new onset or 
the exacerbation of existing medical or psychiatric disor-
ders;9-13 has an estimated societal cost of more than 100 bil-
lion per annum14-16 and an estimated individual cost of 
$1200 in direct health care dollars per affected individual 
per year.16 These data, along with a pivotal commentary 
that called into question the veracity and utility of the con-
cept of secondary insomnia,17 set the stage for a flurry of 
studies showing that targeted treatment for “secondary 
insomnia” is as effective as it is for primary insomnia.18,19 
To our knowledge, there has not been a single study show-
ing that cognitive-behavioral therapy for insomnia (CBT-I) 
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Abstract
“Why treat insomnia?” This question grows out of the perspective that insomnia is a symptom that should only receive 
targeted treatment when temporary relief is needed or until more comprehensive gains may be achieved with therapy 
for the parent or precipitating medical or psychiatric disorders. This perspective, however, is untenable given recent data 
regarding the prevalence, course, consequences, and costs of insomnia. Further, the emerging data that the treatment of 
insomnia may promote better medical and mental health (alone or in combination with other therapies) strongly suggests 
that the question is no longer “why treat insomnia,” but rather “when isn’t insomnia treatment indicated?” This perspective 
was recently catalyzed with the American College of Physicians’ recommendation that chronic insomnia should be treated 
and that the first line treatment should be cognitive-behavioral therapy for insomnia (CBT-I).
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is ineffective in any specific clinical population or demo-
graphic. While not surprising for psychiatric disorders that 
have insomnia as a core feature (eg, depression and anxi-
ety disorders), CBT-I has also been found to be effective 
amongst populations previously thought to be especially 
challenging (eg, patients with PTSD, bipolar disorder, 
psychosis, heart failure, chronic obstructive pulmonary 
disease, sleep apnea, cancer, and chronic pain.18,20-22 In 
addition to these studies, new data has begun to emerge 
showing that the targeted treatment for insomnia also has 
positive clinical effects on the disorders that tend to occur 
comorbidly with insomnia, with average pre-to-post effect 
sizes ranging from –0.03 to 2.48.18 For example, in 2 dem-
onstration projects, CBT-I as an adjuvant treatment to 
escitalopram doubled response and remission rates for 
depression and reduced suicidal ideation by 50%.23,24 
Other examples (that also await confirmation in large 
scale RCTs vs experimental studies or small demonstra-
tion projects) are studies that show that CBT-I increases 
pain tolerance,25-27 promotes better glucose control,28,29 
reduces blood pressure,30 increases beta amyloid clear-
ance,31,32 and enhances immune function.33-35
Taken together, the data from these programs of research 
likely prompted the framers of the DSM-5,36 ICSD-3,37 and 
the ICD-1138 to reclassify insomnia as an independent dis-
order (ie, Insomnia Disorder). During this same time frame, 
this new perspective was catalyzed by the American College 
of Physicians’ recommendation that chronic insomnia 
should be treated in its own right and that the first line 
treatment should be CBT-I.39 These momentous changes 
notwithstanding, most patients are not likely to receive 
treatment for insomnia. This is likely true for a variety of 
reasons. First individuals with sleep continuity disturbance 
(problems falling and/or staying asleep) tend not to seek 
treatment, and when they do, do so when the problem has 
persisted years, if not decades. Second, primary care 
providers tend not to inquire about sleep disturbance (in 
general), or about insomnia (in specific),40-42 despite the 
disorders’ high prevalence amongst their patients and their 
association with psychiatric and medical illness (both as 
risks for new onset disease and exacerbatory factors for 
existing disorders).
Part of this “don’t ask and don’t tell” phenomenon is that 
individuals with insomnia don’t view the problem as one 
that merits professional attention (ie, it will go away on its 
own or can be self- managed). This point of view is not 
unreasonable, it represents the understandable confusion 
between acute and chronic insomnia. The former occurs in 
27% to 37% of the population per annum and resolves in 
47% to 78% of cases).43,44 Another possible reason for the 
lack of patient report of insomnia may be that patients, like 
many healthcare providers, may also labor under the misap-
prehension that their insomnia is secondary to their other 
ailments, and therefore will automatically be addressed as 
their clinician treats the “primary condition”. Finally, pri-
mary care providers often don’t have sufficient sleep medi-
cine training,45,46 and/or simple tools for assessment,47 and/
or the requisite information about what constitutes best 
(evidenced based) practice, and/or easy access to referral 
information. This set of circumstances more than explains 
why clinicians would be disinclined to ask about sleep 
health issues.
In addition to the above considerations, there are 
treatment specific issues. In the case of the medical man-
agement of insomnia, fundamental questions remain unan-
swered about what constitutes best (evidenced based) 
practice. For example: “When is medical treatment opti-
mal?”; “what medications are most effective and safest?”; 
“what medication regimen produces the best and longest 
lasting results?”. The lack of data in this regard makes it 
understandable that clinicians are reluctant to assess and 
treat insomnia, particularly with scheduled medications. In 
the case of the CBT-I, too few patients and clinicians are 
aware that: CBT-I is not simply sleep hygiene; pharmaco-
therapy and behavioral therapy are equipotent during acute 
treatment (first 4-8 weeks of Tx);48-50 CBT-I is a focused 
and short term therapy (6-8 weekly or bi-weekly, 30-90 min-
ute sessions);51-53 CBT-I has enduring benefits following 
treatment discontinuation54,55 and potential positive collat-
eral effects on comorbid illness.18
While the ACP’s recommendation regarding CBT-I rep-
resents a paradigm shift, primary care providers simply do 
not have guidelines regarding “when is CBT-I indicated” or 
“how one goes about referring for CBT-I”. If these factors 
were to be addressed, there would remain 3 profound barri-
ers to accessing CBT-I: (1) there are not enough CBT-I pro-
viders; (2) CBT-I is not on “formulary” for many health 
care systems; and/or (3) CBT-I is often not covered by 3rd 
party payers. Given the recommendation that “chronic 
insomnia should be treated, and ideally with CBT-I,” it may 
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be of use to directly address the issues that are preventing 
good policy from becoming good practice.
Problem: Patients do not view insomnia as a problem 
that warrants direct treatment. Possible Solution: Work 
cooperatively with: (1) industry to create public service/
direct to consumer advertisements (ie, unbranded DCAs) 
that highlight chronic insomnia as a disorder, it’s morbidity, 
and the need for treatment without specific reference to any 
1 therapeutic; and/or (2) prominent stake holders to assist 
with messaging and lobbying efforts. In the absence of (or 
in addition to) DCA’s, informational videos could be placed 
on clinic waiting room video screens.
Problem: Primary care providers do not inquire about 
insomnia, nor do they have training in the assessment and 
treatment of this disorder. Possible Solution: Collaborate 
with primary care organizations to promote the early detec-
tion of sleep disorders (in general) and insomnia (in spe-
cific) via the use of a brief comprehensive screener and/or a 
short insomnia severity measure at annual visits (or as 
needed). The best existing screeners are the GSAQ,56 the 
HSDQ,57 or the SDS-CL-25.58 The best (most well estab-
lished and most commonly used) insomnia instrument is the 
7-item ISI.59,60 Another brief instrument is the 8-item 
PROMIS SD-SF.61,62 In the short term, adoption of the ISI 
or PROMIS SD-SF would be enough to allow for the detec-
tion of undiscussed or occult insomnia and allow for treat-
ment referral. This effort could also potentially include the 
establishment of, or better access to, on-line screeners and 
resources for patients and providers.
Problem: Primary care providers do not have guidelines 
regarding “when is CBT- I indicated”. Possible Solution. In 
the absence of empirical studies, or professional position 
papers, there have been publications on this issue. One such 
publication provided an algorithm for this determination.63 
This issue was also addressed by the ACP’s 2016 publica-
tion. Basically, their position was if the insomnia condition 
is chronic (3 or more days per week for 3 or more months), 
CBT-I is indicated. This may not be so. CBT-I may be con-
traindicated in individuals with seizure disorders, severe 
obstructive sleep apnea, untreated bipolar disorder, in indi-
viduals who are actively suicidal, or in patients with severe 
parasomnias. CBT-I may also not be indicated for those 
with Non-Restorative Sleep syndrome (NRS), mild insom-
nia/short sleepers, or paradoxical insomnia. Perhaps the 
solution to this issue is to refer all cases of chronic insomnia 
to CBT-I providers (Behavioral Sleep Medicine specialists) 
as they will be well positioned to determine if CBT-I is con-
traindicated and/or how to manage complex cases (alone or 
in collaboration with the referring clinician).
Problem: Referral for insomnia care can be difficult. 
Possible Solution: While referral for specialty care is often a 
matter of what is available “in system” and a matter of the 
individual clinicians’ experience with local specialists, there 
are national directories for accredited sleep centers and sleep 
specialist provider directories. These are listed below. 
Perhaps access to the online information and service directo-
ries could be incorporated into the aforementioned public 
services ads (on TV or on waiting room screens). Alternatively, 
before referral to secondary and tertiary care options, primary 
care offices or at least primary care practices embedded in 
larger healthcare systems could utilize online versions of 
CBT-I as a starting point to a step care delivery of service. 
Provided physician education (or program algorithms) are 
sufficiently be able to monitor the outcomes from online ther-
apies so that patients who do not succeed in this first step of 
care could then be referred on to higher levels, perhaps within 
or outside of the primary care office.
Accredited Sleep Centers
http://sleepeducation.org/find-a-facility




Pediatric Sleep Medicine Services / Providers
https://www.babysleep.com/tools/find-a-sleep-center/
Problem: There are too few providers. Possible Solution: 
Steps have been taken over the course of the past 2 decades 
to increase the size of the CBT-I workforce and the avail-
ability of CBT-I. Initial efforts focused on the: (1) creation of 
a certification process for licensed clinicians (eg, physi-
cians, psychologists, nurses, and social workers), initially 
via the ABSM and later via the BBSM; (2) develop ment and 
provision of CE and CME CBT-I trainings [Multidiscipli-
nary continuing education trainings are available (in order 
from most to least established) at University of Rochester/
Pennsylvania (Perlis, 2005), the Department of Defense 
(Brim, 2009), the Veterans Administration (Manber, 2010), 
Ryerson University (Carney, 2015), Oxford University 
(Espie, 2016), University of Arizona (Taylor, 2020).]; and 
(3) establishment of a society dedicated to CBT-I and 
Behavioral Sleep Medicine. Two of the above efforts (the 
establishment of a BSM society and CE/CME trainings) had 
as a foundational mandate extending training and certifica-
tion to master level clinicians. While these efforts have been 
successful, the provider shortage has persisted. Part of the 
problem has to do with reimbursement for CBT-I (ie, reim-
bursement for the intervention in its evidence based form by 
all payers for all practitioners). Some argue that, once this 
issue is resolved, it will serve as the impetus for clinicians 
from diverse fields to seek out training and certification. 
While universal reimbursement may be the impetus, a dedi-
cated lobbying effort will be needed to secure universal 
reimbursement. This can, and will be, bolstered by ongoing 
research efforts that focus on healthcare utilization in 
untreated insomnia and cost outcomes of CBT-I.
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Closing Remark. A decade ago, the question “Why treat 
insomnia?” required the delineation of an argument based 
on evidence that insomnia is “pervasive, pernicious, unre-
mitting, costly, and disabling”.1 Today, the question is not 
“why” but “how”; how do we mainstream sleep health (in 
general) and the assessment and treatment of insomnia (in 
specific). The recommendations proffered here represent 
only a few reasonable ideas. Clearly what is needed is a 
coming together of stakeholders including providers, insur-
ers, industry representatives, policy makers, and patients. 
Daunting as such a convocation may be, a collaboration of 
this type could well yield the desired results: that sleep 
health becomes a part of regular medicine and that all 
patients that need and want CBT-I, can receive CBT-I.
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